Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева; 2ГБОУ ВПО Ставропольский государственный медицинский университет Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310
Список исп. литературыСкрыть список 1. Aldenkamp AP, de Krom M, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia 2003; 44 (Suppl. 4): 21–9. 2. Asnis GM, Chakraburtty A, DuBoff EA et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 1999; 60 (10): 668–76. 3. Baandrup L, Fagerlund B, Jennum P e al. Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial – the SMART trial protocol. BMC Psychiatry 2011; 11: 160. 4. Beckmann H, Moises HW. The cholinolytic biperiden in depression. An acute placebo controlled study. Arch Psychiatr Nervenkr (1970) 1982; 231 (3): 213–20. 5. Blier PE, Mansari M. Serotonin and beyond: therapeutics for major depression. Philos Trans R Soc Lond B Biol Sci 2013; 368 (1615): 20120536. 6. Buffett-Jerrott SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des 2002; 8 (1): 45–58. 7. Cavanna AE, Ali F, Rickards HE, McCorry D. Behavioral and cognitive effects of anti-epileptic drugs. Discov Med 2010; 9 (45): 138–44. 8. Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med 2011; 41: 1165–74. 9. Cricco M, Simonsick EM, Foley DJ. The impact of insomnia on cognitive functioning in older adults. J Am Geriatr Soc 2001; 49 (9): 1185–9. 10. Desmarais JE, Beauclair L, Annable L et al. Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia. Ther Adv Psychopharmacol 2014; 4 (6): 257–67. 11. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. APA, 2015. 12. Dias VV, Balanzá-Martinez V, Soeiro-de-Souza MG et al. Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatr Scand 2012; 126 (5): 315–31. 13. Drake CL, Roehrs T, Roth T. Insomnia causes, consequences, and therapeutics: an overview. Depress Anxiety 2003; 18 (4): 163–76. 14. Furukawa TA, Streiner DL, Young LT. Antidepressant plus benzodiazepine for major depression. Cochrane Database Syst Rev 2001; 2: CD001026. 15. Glass J, Lanctôt KL, Herrmann N et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. Sedative. BMJ 2005; 331 (7526): 1169. 16. Göder R, Nissen C, Rasch B. Sleep, learning and memory: relevance for psychiatry and psychotherapy [Article in German]. Nervenarzt 2014; 85 (1): 50–6. 17. Gorwood P, Corruble E, Falissard B, Goodwin GM. Toxic effects of depression on brain function: impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am J Psychiatry 2008; 165 (6): 731–9. 18. Gosselin P, Ladouceur R, Morin CM et al. Benzodiazepine discontinuation among adults with GAD: A randomized trial of cognitive-behavioral therapy. J Consult Clin Psychol 2006; 74 (5): 908–19. 19. Hoffman EM, Furey ML (October, 2010). Scopolamine Produces Larger Antidepressant and Antianxiety Effects in Women than in Men. Poster presented at annual NIMH Scientific Retreat, Gettysburgh, PA. 20. Ijff DM, Aldenkamp AP. Cognitive side-effects of antiepileptic drugs in children. Handb Clin Neurol 2013; 111: 707–18. 21. International Classification of Disorders, 10th Edition. WHO, 2015. 22. Irwin M, Clark C, Kennedy B et al. Nocturnal catecholamines and immune function in insomniacs, depressed patients, and control subjects. Brain Behav Immun 2003; 17 (5): 365–72. 23. Kajimura N, Mizuki Y, Kai S et al. Memory and cognitive impairments in a case of long-term trihexyphenidyl abuse. Pharmacopsychiatry 1993; 26 (2): 59–62. 24. McIntyre RS, Cha DS, Soczynska JK et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety 2013; 30 (6): 515–27. 25. Nagane A, Baba H, Nakano Y et al. Comparative study of cognitive impairment between medicated and medication-free patients with remitted major depression: class-specific influence by tricyclic antidepressants and newer antidepressants. Psychiatry Res 2014; 218 (1–2): 101–5. 26. Nolen WA, Haffmans PM, Bouvy PF, Duivenvoorden HJ. Hypnotics as concurrent medication in depression. A placebo-controlled, double-blind comparison of flunitrazepam and lormetazepam in patients with major depression, treated with a (tri)cyclic antidepressant. J Affect Disord 1993; 28 (3): 179–88. 27. Ramaekers JG, Louwerens JW, Muntjewerff ND et al. Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J Clin Psychopharmacol 1999; 19 (3): 209–21. 28. Roth T, Zammit GK, Scharf MB, Farber R. Efficacy and safety of as-needed, post bedtime dosing with indiplon in insomnia patients with chronic difficulty maintaining sleep. Sleep 2007; 30 (12): 1731–8. 29. Sambeth A, Riedel WJ, Klinkenberg I et al. Biperiden selectively induces memory impairment in healthy volunteers: no interaction with citalopram. Psychopharmacology (Berl) 2015; 232 (11): 1887–97. 30. Soehner AM, Kaplan KA, Harvey AG. Prevalence and clinical correlates of co-occurring insomnia and hypersomnia symptoms in depression. J Affect Disord 2014; 167: 93–7. 31. Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry 2005; 66 (Suppl. 2): 9–13. 32. Stewart SH, Westra HA. Benzodiazepine side-effects: from the bench to the clinic. Curr Pharm Des 2002; 8 (1): 1–3. 33. Sunderajan P, Gaynes BN, Wisniewski SR et al. Insomnia in patients with depression: a STAR*D report. CNS Spectr 2010; 15 (6): 394–404. 34. Veselinović T, Vernaleken I, Janouschek H et al. Effects of anticholinergic challenge on psychopathology and cognition in drug-free patients with schizophrenia and healthy volunteers. Psychopharmacology (Berl) 2015; 232 (9): 1607–17. 35. Walsh JK. Pharmacologic management of insomnia. J Clin Psychiatry 2004; 65 (Suppl. 16): 41–5. 36. Zisapel N. Sleep and sleep disturbances: biological basis and clinical implications. Cell Mol Life Sci 2007; 64 (10): 1174–86.